Fortrea Holdings (FTRE) Asset Writedowns and Impairment (2023 - 2025)
Fortrea Holdings (FTRE) posted Asset Writedowns and Impairment of -$785.9 million for Q4 2025, down 198.64% on a QoQ basis from $796.7 million in Q3 2025, and down 4193.23% year-over-year from $19.2 million in Q4 2024.
Fortrea Holdings (FTRE) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Fortrea Holdings' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at -$785.9 million for Q4 2025.
- Quarterly Asset Writedowns and Impairment fell 4193.23% year-over-year to -$785.9 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $7.5 million (up 66.67% YoY) and the FY2025 annual result came in at $12.0 million, down 50.0% from the prior year.
- Asset Writedowns and Impairment was -$785.9 million for Q4 2025 at Fortrea Holdings, down from $796.7 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $796.7 million in Q3 2025 and bottomed at -$785.9 million in Q4 2025.
- A 3-year average of $3.6 million and a median of $8.4 million in 2024 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 2637.26% in 2025, while the deepest fall reached 4193.23% in 2025.
- Fortrea Holdings' Asset Writedowns and Impairment stood at -$21.9 million in 2023, then soared by 187.67% to $19.2 million in 2024, then slumped by 4193.23% to -$785.9 million in 2025.
- Business Quant data shows FTRE's Asset Writedowns and Impairment at -$785.9 million in Q4 2025, $796.7 million in Q3 2025, and -$3.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Fortrea Holdings | 1.79 Bn | 1.64 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -785.90 Mn |
| Dec 31, 2025 | -785.90 Mn |
| Sep 30, 2025 | 796.70 Mn |
| Sep 30, 2025 | 796.70 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Jun 30, 2025 | -3.30 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 19.20 Mn |
| Dec 31, 2024 | 19.20 Mn |
| Sep 30, 2024 | -31.40 Mn |
| Sep 30, 2024 | -31.40 Mn |
| Jun 30, 2024 | 12.20 Mn |
| Jun 30, 2024 | 12.20 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Dec 31, 2023 | -21.90 Mn |
| Dec 31, 2023 | -21.90 Mn |
| Sep 30, 2023 | 21.90 Mn |
| Sep 30, 2023 | 21.90 Mn |